Table 3. The effect of coronary revascularization procedures and secondary prevention therapy during follow-up (as time-varying covariates) on longer-term (31 days to 5 years) mortality.

		All-cause mortality			CHD mortality
Time-varying covariate	n/N (%)	Unadjusted hazard ratios (95% CI)	Adjusted hazard ratios (95% CI) *	n/N (%)	Unadjusted hazard ratios (95% CI)	Adjusted hazard ratios (95% CI) *
CABG	10/159 (6.3)	0.88 (0.75, 1.04)	0.96 (0.81–1.14)	9/159 (5.7)	0.44 (0.22, 0.85) †	0.69 (0.35–1.35)
PTCA	17/222 (7.7)	0.86 (0.75, 0.99) †	0.97 (0.84–1.12)	10/222 (4.5)	0.27 (0.15, 0.51) §	0.49 (0.26–0.93) †
ACE inhibitors	279/1294 (21.6)	1.06 (0.97, 1.16)	1.13 (1.02–1.24) †	211/1294 (16.3)	1.55 (1.25, 1.93) §	1.74 (1.38–2.21) §
β-blockers	207/1364 (15.2)	0.81 (0.74, 0.88) §	0.89 (0.80–0.98) †	139/1364 (10.2)	0.41 (0.33, 0.51) §	0.58 (0.46–0.74) §
Anti-platelets	384/1802 (21.3)	0.98 (0.86, 1.11)	1.14 (0.99–1.32)	276/1802 (15.3)	1.03 (0.80, 1.34)	1.28 (0.96–1.71)
Statins	195/1456 (13.3)	0.76 (0.69, 0.83) §	0.81 (0.72–0.90) §	143/1456 (9.8)	0.41 (0.33, 0.52) §	0.60 (0.47–0.77) §

^*Adjusted for baseline characteristics and all time varying covariates.

^†p<0.05;

^‡p<0.01;

^§p<0.001.

ACE = angiotensin converting enzyme; AMI = acute myocardial infarction; CHD = coronary heart disease; CABG = coronary artery bypass grafting; PTCA = percutaneous transluminal coronary angioplasty.